Evaluation of Urinary Plasminogen Activator, Its Receptor, Matrix Metalloproteinase-9, and von Willebrand Factor in Pancreatic Cancer

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4935-4943

  Harvey, Shashi R ^a,b   Hurd, Thelma C ^a   Markus, Gabor ^a   Martinick, Maisie I ^a   Penetrante, Remedios M ^a   Tan, Dongfeng ^a   Venkataraman, Preeti ^c   DeSouza, Nisha ^a   Sait, Sheila N J ^a   Driscoll, Deborah L ^a   Gibbs, John F ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; GELATINASE B; MONOCLONAL ANTIBODY; PLASMIN; PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR; VON WILLEBRAND FACTOR;

ADVANCED CANCER; ARTICLE; BASEMENT MEMBRANE; CANCER PATIENT; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROVASCULATURE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STROMA CELL; TUMOR LOCALIZATION;

BIOTINYLATION; DNA, COMPLEMENTARY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 9; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES; PANCREATIC NEOPLASMS; PROGNOSIS; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 10744232549     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gibbs, J. F., Smith, J. L., and Douglass, H. O. Surgery of pancreatic cancer. In: A. K. Rustgi, and J. Crawford (eds.). Gastrointestinal Cancers: Biology and Clinical Management, pp. 541-547. Philadelphia: W. B. Saunders Publishers, 2003.
2. Kern, S., Hruban, R., Hollingsworth, M. A., Brand, R., Adrian T. E., Jaffee, E., Tempero, M. A. A white paper: the product of a pancreas cancer think tank. Cancer Res., 61: 4923-4932, 2001.
3. Bramhall, S. R., Stamp, G. W. H., Lemoine, N. R., Neoptolemos, J. P. The Matrix Metalloproteinases and Their Inhibitors in Pancreatic Cancer. Pancreatic Cancer: Molecular and Clinical Advances, Vol. 6, pp. 68-88. Oxford: Blackwell Science Publishers. 1996.
4. Murphy, G., and Grantilovic, J. Proteolysis and cell migration: creating a path? Curr. Opin. Cell. Biol., 11: 614-621, 1999.
5. Andreasen, P. A., Kjoller, L., Christensen, L., Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
6. Duffy, M. J. Proteases as prognostic markers in cancer. Clin. Can. Res., 2: 613-618, 1996.
7. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brunner, N., Janicki, F., Meijer-vanGelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., Klijn, J. G. The urokinase system of plasminogen activation and Prognosis in 2780 breast cancer patients. Cancer Res., 60: 636-643, 2000.
8. Ghosh, S., Elleroboer, S. M., Wu, Y., and Stack, M. D. Tumor-cell mediated proteolysis: regulatory mechanisms and functional consequences: Fibrinolysis and Proteolysis, 14: 87-87, 2000.
9. Rabbani, S. A., and Mazar, A. P. The role of the plasminogen activation system in angiogenesis and metastasis. Surg. Oncol. Clin. N. Am., 10: 393-415, 2001.
10. McCawley, L. J., and Matrisan, L. M. Matrix metalloproteinases: they are not just for matrix anymore. Curr. Opin. Cell. Biol., 13: 534-540, 2001.
11. Patterson, B. C., and Sang, Q. A. Angiostatin-converting enzyme activities of human Matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem., 272: 28823-28825, 1997.
12. Ribatti, D., Leali, D. Vacca, A., Guiliani, R., Gualandris, A., Roncali, L., Nolli, M. L., Presta, M. In vivo angiogenic activity of urokinase: role of endogenous fibroblast-growth factor-2. J. Cell. Sci., 112: 4213-4221, 1999.
13. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol., 2: 737-744, 2000.
14. O'Mahoney, C. A., Seidel, A., Albo, D., Tuszynski, G. P., Berger, D. H. Angiostatin generation by human pancreatic cancer. J. Surg. Res., 77: 55-58, 1998.
15. Takeuchi, Y., Nakao, A., Harada, A., Nonami, T., Fukatsu, T., Takagi, H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am. J. Gastroenterol., 88: 1928-1933, 1993.
16. Cantero, D. Friess, H., Deflorin, J., Zimmermann, A., Brundler, M. A., Riesle, E., Korc, M., Buchler, M. N. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75: 388-395, 1997.
17. Rabbani, S. A. Metalloproteinases and urokinase in angiogenesis and tumor progression. In Vivo, 12: 135-142, 1998.
18. Bardesy, N., and DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer, 2: 897-909, 2002.
19. Harvey, S., Sait, S. N., Xu, Y., Xu, Y., Bailey, J. L., Penetrante, R. M., Markus, G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am. J. Pathol., 155: 1115-1120, 1999.
20. Weidner, N., and Folkman, J. Tumor vascularity as a prognostic factor in cancer. In: V. T. DeVita, S. Hellman, and S. A. Rosenburg (eds.), Important Advances in Oncology, pp. 167-190. Philadelphia: Lippincott-Raven Publishers, 1996.
21. Markus, G. Plasminogen activators in malignant growth. In: J. F. Davids, F. Bachman, and C. A. Bouvier (eds.), Progress in Fibrinolysis, Vol. 6, pp. 587-604. Edinborough: Churchill Livingstone Publishers, 1983.
22. Kohga, S., Harvey, S., Suzumiya, J., Sumiyoshi, A., Markus, G. Comparison of the immunohistological localization of urokinase in normal and cancerous human colon tissue. Fibrinolysis, 3: 17-22, 1989.
23. Buo, L., Meling, G. I., Karlsrud, T. S., Johnansen, H. T., and Aasen, A. O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum. Pathol., 26: 1133-1138, 1995.
24. Duffy, M. J., Maguire, T. M., McDermott, E. W., and O'Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Conc., 17: 130-135, 1999.
25. Sier, C. F. Stephens, R., Bizik, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Dano, K., Brunner, N., Blasi, F. The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res., 58: 1843-1849, 1998.
26. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K., Grondahl-Hansen J. Prognostic impact of urokinase urokinase receptor and type I activator in squamous and large cell lung cancer tissue. Cancer Res., 54: 1421-1475, 1994.
27. Schmalfeldt, B. Prechtel, D., Harting, K., Spathe, K., Rutke, S., Konik, E., Frieman, R., Berger, U., Schmitt, M., Kuhn, W., Lengyel, E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer 2001. Clin. Cancer Res., 7: 2396-2404, 2001.
28. Ellis, V., Behrendt, N., and Dano, K. Cellular receptor for urokinase type plasminogen activator function in cell-surface proteolysis. Methods Enzymol., 222: 223-231, 1993.
29. Pyke, C., Kristensen, P., Ralfkiaer, E., Grondahl-Hansen, J., Eriksen, J., Blasi, F., Dano, K., Urokinase-type plasminogen activator is expressed in stromal cells at invasive foci in human colon adenocarcinomas 1991. Am. J. Pathol., 138: 1059-1067, 1991.
30. Nielsen, B. S., Sehested, M., Duun, S., Rank, F., Timshel, S., Rygaard, J., Johnsen, M., Dano, K. Urokinase plasminogen activator's localized in stromal cells in ductal breast cancer. Lab. Investig., 81: 1485-1501, 2001.